* Rxsight Inc RXST.OQ RXST.O is expected to show a rise
in
quarterly revenue when it reports results on March 6.
* The Aliso Viejo California-based company is expected to
report
a 82.4% increase in revenue to $15.375 million from $8.43
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Rxsight Inc is for
a loss
of 75 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Rxsight Inc
is
$22, above its last closing price of $13.36.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.71 -0.71 -0.61 Beat 14.5
Jun. 30 2022 -0.69 -0.69 -0.61 Beat 12.2
Mar. 31 2022 -0.65 -0.65 -0.64 Beat 1
Dec. 31 2021 -0.73 -0.68 -0.58 Beat 15
Sep. -0.63 -0.62 -0.68 Missed -9.7
30 2021
Jun. 30 2021 -0.70 -0.70 -0.51 Beat 27.5
This summary was machine generated March 3 at 21:11 GMT. All
figures in US dollars unless otherwise stated